[18F]AlF-PSMA Probe for Prostate Cancer Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET imaging technologies for prostate cancer lack effective 18F labeling of PSMA-targeting molecular probes, which are essential for early and accurate diagnosis, as existing 68Ga-labeled probes have limitations such as high bladder uptake and longer imaging times.
Innovation Solution
Development of an [18F]AlF labeled PSMA targeting molecular probe using the bifunctional linker HBED-CC, where 18F is incorporated into P16-093 through a specific preparation method involving cyclotron-produced 18F enrichment and reaction with AlCl3, resulting in a probe with superior biological properties and reduced bladder uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If 68Ga-labeled PSMA-targeted PET imaging drugs are used, then tumor imaging capability is improved, but bladder radiation uptake increases and imaging time is extended
Solution Approach 1:
The patent changes the radionuclide from 68Ga to 18F and modifies the chemical coordination structure by introducing AlF complex formation. This parameter change in the labeling chemistry results in reduced bladder radiation uptake while maintaining tumor imaging capability, as the 18F-AlF complex has different biodistribution characteristics compared to 68Ga-PSMA-11
2Measurement precision
If 68Ga-labeled PSMA-targeted PET imaging drugs are used, then tumor imaging capability is improved, but imaging time is extended
Solution Approach 1:
The patent changes the radionuclide half-life parameter from 68Ga (68.1 min) to 18F (109.8 min) and modifies the complex formation kinetics by introducing AlF coordination. This enables faster tumor uptake and imaging, reducing the time required for diagnostic imaging while maintaining precision
3Speed
If 18F labeling is implemented for PSMA-targeting molecular probes, then imaging speed is improved, but labeling stability and reliability become challenging
Solution Approach 1:
The patent uses AlF as an intermediary complexing agent between the 18F radionuclide and the PSMA-targeting molecular probe. The AlF complex acts as a stable intermediary that facilitates 18F incorporation while ensuring labeling stability, solving the reliability challenge of direct 18F labeling
Solution Approach 2:
The patent creates a composite labeling system combining 18F, AlF, and the HBED-CC bifunctional linker in a coordinated complex structure. This composite approach enhances both the speed of imaging and the stability of labeling by leveraging the synergistic properties of all components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The [18F]AlF labeled PSMA probe demonstrates high stability, rapid tumor uptake, and reduced bladder radiation, enabling earlier and more effective imaging of prostate cancer with potential for improved clinical applications in diagnosis and treatment guidance.
Implementation Method 1
18F− was prepared on a cyclotron by nuclear reaction 18 O(p,n)18F
Implementation Method 2
68Ga-P16-093 is coordinated with 68Ga3+ (coordination constant ̃38.5) by using HBED-CC as a bifunctional linker
Data Source
AI summary
A radiopharmaceuticals in clinical popularization is facilitated. By means of the biological characteristic of specifically targeting PSMA of the [18F]AlF-P16-093, the labeled product has important potential clinical values in the aspects of early diagnosis, preoperative staging, treatment guidance, recurrence and metastasis focus detection of prostate cancer.